Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Uno studio di TP-3654 orale in pazienti con mielofibrosi

30 settembre 2026 aggiornato da: Sumitomo Pharma America, Inc.

Uno studio di fase 1/2, in aperto, aumento della dose, sicurezza, farmacocinetica e farmacodinamica del TP-3654 orale in pazienti con mielofibrosi primaria o secondaria a rischio intermedio o alto

This study is a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of nuvisertib (TP-3654) in patients with intermediate or high-risk primary or secondary MF.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Descrizione dettagliata

Arm 1 will enroll patients who have been previously treated and failed on a JAK inhibitor or ineligible to receive treatment with a JAK inhibitor.

Arm 2 will enroll patients who are on a stable dose of ruxolitinib, but who have either lost response or had a suboptimal or plateau in response.

Arm 3 will enroll patients who have been previously treated with a JAK inhibitor (except momelotinib)

Tipo di studio

Interventistico

Iscrizione (Stimato)

240

Fase

  • Fase 2
  • Fase 1

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Luoghi di studio

      • Adelaide, Australia
        • Reclutamento
        • Icon Cancer Centre (Ashford Cancer Centre Research)
        • Contatto:
    • South Australia
      • Adelaide, South Australia, Australia
    • Victoria
      • Box Hill, Victoria, Australia
        • Reclutamento
        • Eastern Health Box Hill Hospital
        • Contatto:
          • SMPA Investigative Site
      • Clayton, Victoria, Australia
        • Reclutamento
        • Monash University
        • Contatto:
          • SMPA Investigative Site
      • Fitzroy, Victoria, Australia
        • Reclutamento
        • St Vincent's Hospital Melbourne
        • Contatto:
          • SMPA Investigative Site
      • Melbourne, Victoria, Australia
        • Reclutamento
        • Peter McCallum Center
        • Contatto:
          • SMPA Investigative Site
      • Richmond, Victoria, Australia
        • Reclutamento
        • Epworth Healthcare
        • Contatto:
          • SMPA Investigative Site
      • Antwerp, Belgio, 2020
        • Reclutamento
        • ZNA Cadix
        • Contatto:
          • SMPA Investigative Site
      • Antwerp, Belgio, 2030
        • Reclutamento
        • ZNA Middelheim
        • Contatto:
          • SMPA Investigative Site
      • Ghent, Belgio, 9000
        • Reclutamento
        • Universitair Ziekenhuis Gent
        • Contatto:
          • SMPA Investigative Site
      • Liège, Belgio, 4000
        • Reclutamento
        • CHU de Liege
        • Contatto:
          • SMPA Investigative Site
    • Vlaams-Brabant
      • Leuven, Vlaams-Brabant, Belgio, 3000
        • Reclutamento
        • University Hospitals Leuven
        • Contatto:
          • SMPA Investigative Site
    • Alberta
    • British Columbia
      • Vancouver, British Columbia, Canada, V6T 1Z3
        • Reclutamento
        • University of British Columbia
        • Contatto:
          • SMPA Investigative Site
      • Vancouver, British Columbia, Canada, V6T 1Z3
        • Reclutamento
        • St. Paul's Hospital Hematology/Oncology Research
        • Contatto:
    • Ontario
      • Hamilton, Ontario, Canada, L8V 5C2
        • Reclutamento
        • Juravinski Cancer Center
        • Contatto:
          • SMPA Investigative Site
      • Toronto, Ontario, Canada, M5G 2M9
        • Reclutamento
        • Princess Margaret Cancer Center
        • Contatto:
    • Quebec
      • Montreal, Quebec, Canada, H3T 1E2
        • Reclutamento
        • Jewish General Hospital
        • Contatto:
          • SMPA Investigative Site
      • Amiens, Francia, 80054
        • Reclutamento
        • Centre Hospitalier Universitaire D'Amiens
        • Contatto:
          • SMPA Investigative Site
      • Angers, Francia, 9000
        • Reclutamento
        • CHU Angers
        • Contatto:
          • SMPA Investigative Site
      • Lyon, Francia, 69495
        • Reclutamento
        • Centre Hospitalier Lyon Sud
        • Contatto:
          • SMPA Investigative Site
      • Nice, Francia, 06200
        • Reclutamento
        • Hospitalier Universitaire (CHU) de Nice - Hopital de l'Archet
        • Contatto:
          • SMPA Investigative Site
      • Nîmes, Francia, 30029
        • Reclutamento
        • Institut de cancerologie du Gard
        • Contatto:
          • SMPA Investigative Site
      • Nîmes, Francia
        • Reclutamento
        • Institut de cancerologie du Gard
        • Contatto:
          • SMPA Investigative Site
      • Paris, Francia, 75010
        • Reclutamento
        • Hospital Saint Louis
        • Contatto:
          • SMPA Investigative Site
      • Poitiers, Francia, 86021
        • Reclutamento
        • University Hospital of Poitiers
        • Contatto:
          • SMPA Investigative Site
      • Villejuif, Francia, 94805
        • Reclutamento
        • Institut Gustave Roussy
        • Contatto:
          • SMPA Investigative Site
      • Halle, Germania
        • Reclutamento
        • Universitätsmedizin Halle
        • Contatto:
          • SMPA Investigative Site
      • Lübeck, Germania
        • Reclutamento
        • Universitätsklinikum Schleswig-Holstein
        • Contatto:
          • SMPA Investigative Site
      • Aichi, Giappone
      • Aomori, Giappone
        • Reclutamento
        • Aomori Prefectural Central Hospital
        • Contatto:
      • Chiba, Giappone
        • Reclutamento
        • National Cancer Center Hospital East
        • Contatto:
      • Fukuoka, Giappone
      • Hokkaido, Giappone
        • Reclutamento
        • Hokkaido University Hospital
        • Contatto:
      • Kamakura, Giappone, 247-8533
        • Reclutamento
        • Shonan Kamakura General Hospital
        • Contatto:
      • Miyazaki, Giappone
        • Reclutamento
        • University of Miyazaki Hospital
        • Contatto:
      • Okayama, Giappone
        • Reclutamento
        • Okayama University Hospital
        • Contatto:
      • Osaka, Giappone
        • Reclutamento
        • The University of Osaka Hospital
        • Contatto:
          • Michiko Ichii, MD
          • Numero di telefono: 06-6879-5111
      • Saitama, Giappone
        • Completato
        • Saitama Medical Center
      • Sendai, Giappone
        • Reclutamento
        • Tohoku University Hospital
        • Contatto:
          • Noriko Fukuhara, MD
          • Numero di telefono: 022-717-7000
      • Shizuoka, Giappone
        • Completato
        • Shizuoka Cancer Center
      • Tokyo, Giappone, 160-0023
        • Reclutamento
        • Tokyo Medical University Hospital
        • Contatto:
      • Tokyo, Giappone
        • Reclutamento
        • Juntendo University Hospital
        • Contatto:
      • Tokyo, Giappone, 179-0072
        • Reclutamento
        • Nerima Hikarigaoka Hospital
        • Contatto:
      • Tsu, Giappone
      • Alessandria, Italia, 15121
        • Reclutamento
        • Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo
        • Contatto:
          • SMPA Investigative Site
      • Aviano, Italia, 33081
        • Reclutamento
        • Istituto Nazionale Tumori, IRCCS Centro di Riferimento Oncologico di Aviano
      • Bologna, Italia, 40138
        • Reclutamento
        • IRCCS Azienda Ospedaliero -Universitaria Di Bologna - Dipartimento Malattie Oncologiche ed Ematologiche - UO Ematologia
        • Contatto:
          • SMPA Investigative Site
      • Brescia, Italia
        • Reclutamento
        • ASST - Spedali Civili di Brescia
        • Contatto:
          • SMPA Investigative Site
      • Meldola, Italia, 47014
        • Reclutamento
        • IRCCS istituto Romagnolo per lo studio dei tumori "Dino Amadori"
        • Contatto:
          • SMPA Investigative Site
      • Milan, Italia, 20122
        • Reclutamento
        • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
        • Contatto:
          • SMPA Investigative Site
      • Torino, Italia, 10126
        • Reclutamento
        • Azienda Ospedaliera Universitaria Citta' Della Salute E della Scienza di Torino
        • Contatto:
          • SMPA Investigative Site
      • Lincoln, Regno Unito
        • Reclutamento
        • Lincoln County Hospital
        • Contatto:
          • SMPA Investigative Site
      • Lincoln, Regno Unito
        • Reclutamento
        • United Lincolnshire Hospitals NHS Trust - Pilgrim Hospital
        • Contatto:
          • SMPA Investigative Site
      • London, Regno Unito
        • Reclutamento
        • University College London Hospital's NHS foundation Trust
        • Contatto:
          • SMPA Investigative Site
      • Oxford, Regno Unito
        • Reclutamento
        • Oxford University Hospitals NHS Foundation
        • Contatto:
          • SMPA Investigative Site
      • Barcelona, Spagna
        • Reclutamento
        • Hospital Universitario y Politecnico La Fe
        • Contatto:
          • SMPA Investigative Site
      • Barcelona, Spagna
        • Reclutamento
        • Institut Catala d'Oncologia
        • Contatto:
          • SMPA Investigative Site
      • Salamanca, Spagna
        • Reclutamento
        • Hospital Universitario de Salamanca
        • Contatto:
          • SMPA Investigative Site
    • Alabama
      • Birmingham, Alabama, Stati Uniti, 35294
        • Reclutamento
        • University of Alabama
        • Contatto:
          • Tiffany Hill
          • Numero di telefono: 205-934-9591
    • Arizona
      • Tucson, Arizona, Stati Uniti, 85724
        • Reclutamento
        • The University of Arizona Cancer Center
        • Contatto:
    • California
      • Duarte, California, Stati Uniti, 91010
        • Reclutamento
        • City of Hope
        • Contatto:
      • Los Angeles, California, Stati Uniti, 90033
        • Reclutamento
        • University of Southern California
        • Contatto:
      • Newport Beach, California, Stati Uniti, 92663
        • Reclutamento
        • Hoag Family Cancer Institute
        • Contatto:
    • Colorado
    • Connecticut
      • New Haven, Connecticut, Stati Uniti, 06510
        • Reclutamento
        • Yale School of Medicine
        • Contatto:
    • Florida
      • Gainesville, Florida, Stati Uniti, 32608
        • Completato
        • University of Florida Health Shands Cancer Hospital
      • Miami, Florida, Stati Uniti, 33136
        • Reclutamento
        • University of Miami
        • Contatto:
      • Miami, Florida, Stati Uniti, 33176
        • Reclutamento
        • Baptist Health - Miami Cancer Institute
        • Contatto:
    • Georgia
      • Atlanta, Georgia, Stati Uniti, 30322
    • Illinois
      • Chicago, Illinois, Stati Uniti, 60637
    • Maryland
      • Baltimore, Maryland, Stati Uniti, 21201
        • Reclutamento
        • University of Maryland
        • Contatto:
          • Maria Baer, MD
          • Numero di telefono: 410-328-8708
          • Email: mbaer@umm.edu
    • Massachusetts
      • Boston, Massachusetts, Stati Uniti, 02114
        • Reclutamento
        • Massachusetts General Hospital
        • Contatto:
    • Michigan
      • Ann Arbor, Michigan, Stati Uniti, 48109
        • Reclutamento
        • University of Michigan
        • Contatto:
    • Minnesota
      • Minneapolis, Minnesota, Stati Uniti, 55455
        • Reclutamento
        • University of Minnesota
        • Contatto:
    • Missouri
      • St Louis, Missouri, Stati Uniti, 63110
        • Reclutamento
        • Washington University of Medicine
        • Contatto:
    • New Jersey
      • Hackensack, New Jersey, Stati Uniti, 07601
        • Reclutamento
        • John Theurer Cancer Center at Hackensack University Medical Center
        • Contatto:
    • New York
      • Buffalo, New York, Stati Uniti, 14263
        • Completato
        • Roswell Park Comprehensive Cancer Center
      • New York, New York, Stati Uniti, 10065
        • Reclutamento
        • Memorial Sloan Kettering Cancer Center
        • Contatto:
      • New York, New York, Stati Uniti, 10029
      • New York, New York, Stati Uniti, 10065
        • Reclutamento
        • Weill Cornell Medical Center
        • Contatto:
      • The Bronx, New York, Stati Uniti, 10461
    • North Carolina
      • Durham, North Carolina, Stati Uniti, 27710
    • Ohio
      • Columbus, Ohio, Stati Uniti, 43210
    • South Carolina
      • Charleston, South Carolina, Stati Uniti, 29425
        • Reclutamento
        • Medical University of South Carolina
        • Contatto:
    • Tennessee
      • Nashville, Tennessee, Stati Uniti, 37232
        • Reclutamento
        • Vanderbilt University
        • Contatto:
          • SMPA Investigative Site
      • Nashville, Tennessee, Stati Uniti, 37203
    • Texas
      • Houston, Texas, Stati Uniti, 77054
        • Reclutamento
        • MD Anderson Cancer Center
        • Contatto:
    • Utah
      • Salt Lake City, Utah, Stati Uniti, 84112
        • Reclutamento
        • Huntsman Cancer Institute
        • Contatto:
    • Virginia
      • Charlottesville, Virginia, Stati Uniti, 22903
        • Reclutamento
        • University of Virginia Cancer Center
        • Contatto:
    • Washington
      • Seattle, Washington, Stati Uniti, 98109
        • Reclutamento
        • University of Washington - Fred Hutchinson Cancer Center
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Patients must meet all of the following inclusion criteria to be eligible:

Nuvisertib (TP-3654) Monotherapy Arm:

  • Confirmed pathological diagnosis of primary myelofibrosis (PMF) or post-PV-MF/post-ET- MF and intermediate or high-risk primary or secondary MF
  • Previously treated with JAK inhibitor(s) and is intolerant, resistant, refractory or has lost response to the JAK inhibitor(s) or is ineligible to be treated with JAK inhibitor
  • Fulfill the following clinical laboratory parameters:
  • Platelet count ≥ 25 x 10^9 /L, without assistance of growth factors or platelet transfusions
  • ANC ≥ 1 x 10^9/L without assistance of granulocyte growth factors
  • Peripheral blood blast count < 5%
  • ECOG performance status ≤ 1
  • Life expectancy ≥ 6 months
  • Adequate renal function
  • Adequate hepatic function
  • Adequate coagulation function
  • Splenomegaly (spleen volume of ≥ 450 cm3 by MRI or CT scan) within 2 weeks prior to Cycle 1 Day 1.
  • Dose escalation: At least 2 symptoms measurable (score ≥ 1) using the MF-SAF
  • Dose expansion: At least 2 symptoms measurable with each score of ≥ 3 or a total average score of ≥ 10 per MFSAF

Nuvisertib (TP-3654) + Ruxolitinib Arm:

  • Confirmed pathological diagnosis of PMF or post-PV-MF/post ET- MF and intermediate or high-risk primary or secondary MF
  • On ruxolitinib treatment for ≥ 6 months, and on a stable dose of ruxolitinib (5 to 25 mg BID) for ≥ 8 weeks prior to the first dose of nuvisertib, but has either lost response or had a suboptimal or plateau in response
  • Fulfills the following clinical laboratory parameters:
  • Platelet count ≥ 50 × 10^9/L (without assistance of growth factors or platelet transfusions)
  • ANC ≥ 1 × 109/L without assistance of granulocyte growth factors
  • Peripheral blood blast count < 5% at screening
  • Adequate renal function
  • Adequate hepatic function
  • Adequate coagulation function
  • Splenomegaly (spleen volume of ≥ 450 cm3 by MRI/CT scan) within 2 weeks prior to Cycle 1 Day 1
  • At least 2 symptoms measurable with each score ≥ 3 or a total average score of ≥ 10 per MFSAF v4.0
  • ECOG performance status ≤ 1
  • Life expectancy ≥ 6 months

Nuvisertib (TP-3654) + Momelotinib Arm

  • Confirmed pathological diagnosis of PMF or post-PV-MF/post ET-MF and intermediate or high-risk primary or secondary MF
  • Previously treated with an approved JAK inhibitor (except momelotinib) for PMF or Post-PV/ET MF for ≥ 12 weeks, or ≥ 4 weeks if JAK inhibitor therapy was complicated by a transfusion requirement of ≥ 4 units of red blood cells in 8 weeks, or Grade 3/4 AEs of thrombocytopenia, anemia, or hematoma
  • Fulfills the following clinical laboratory parameters:
  • Anemic, defined as Hb <10 g/dL or requiring RBC transfusion at baseline
  • Platelet count ≥ 50 × 109/L (without assistance of growth factors or platelet transfusions)
  • ANC ≥ 1 × 109/L without assistance of granulocyte growth factors
  • Peripheral blood blast count < 5% at screening
  • Adequate renal function
  • Adequate hepatic function
  • Adequate coagulation function
  • Splenomegaly (spleen volume of ≥ 450 cm3 by MRI/CT scan) within 2 weeks prior to Cycle 1 Day 1
  • At least 2 symptoms measurable with each score of ≥ 3 or a total average score of ≥ 10 per MFSAF v4.0
  • ECOG performance status ≤ 1
  • Life expectancy ≥ 6 months

Patients meeting any one of these exclusion criteria will be prohibited from participating in this study:

Nuvisertib (TP-3654) Monotherapy Arm:

  • Received previous systemic antineoplastic therapy or any experimental therapy within 2 weeks or 5 half-lives, whichever is longer, prior to Cycle 1 Day 1. Hydroxyurea or anagrelide are allowed up to 24 hours prior to Cycle 1 Day 1).
  • Major surgery within 4 weeks prior to Cycle 1 Day 1 and/or not recovered adequately from from surgery prior to first dose.
  • Splenic irradiation within 6 months prior to Screening or prior splenectomy.
  • Prior allogeneic stem cell transplant within the last 6 months.
  • Eligible for allogeneic bone marrow or stem cell transplantation.
  • Unresolved Grade ≥ 2 non-hematological toxicity related to prior treatment
  • History of symptomatic congestive heart failure, or myocardial infarction, or uncontrolled arrhythmia within 6 months prior to Cycle 1 Day 1; left ventricular ejection fraction (LVEF) < 45% by echocardiogram within 4 weeks prior to Cycle 1 Day 1.
  • Corrected QT interval > 480msec.
  • Prior or concurrent malignancy that could interfere with the investigational regime.
  • Known history of chronic liver disease, e.g. portal hypertension or any of its complications, cirrhosis, Child-Pugh C, auto-immune hepatitis, alpha-1 anti-trypsin deficiency, Wilson's disease, etc.
  • Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic antimicrobial within 1 week prior to Cycle 1 Day 1.
  • Chronic active or acute viral hepatitis A, B, or C infection (testing for hepatitis B and C are required)
  • Exhibited allergic reactions or sensitivity to nuvisertib, or similar compound.
  • Medical condition or GI tract surgery that could impair absorption or result in short bowel syndrome with diarrhea.
  • Systemic steroid therapy (>10 mg daily prednisone or equivalent) within 1 week prior to the first dose of study treatment (note: topical, inhaled, nasal, and ophthalmic steroids are not prohibited).
  • Known clinically significant anemia due to iron, vitamin B12, or folate deficiencies, or autoimmune or hereditary hemolytic anemia, or thalassemia, or severe GI bleeding.
  • Pregnant or breastfeeding
  • Currently receiving any other investigational agent.

Nuvisertib (TP-3654) + Ruxolitinib Arm:

  • Received previous systemic antineoplastic therapy (other than ruxolitinib) or any other experimental therapy within 2 weeks or 5 half-lives, whichever is longer, prior to Cycle 1 Day 1 (Note: Prior treatment with nuvisertib is not allowed. Hydroxyurea or anagrelide are allowed up to 24 hours prior to Cycle 1 Day 1).
  • Received systemic steroid therapy (>10 mg daily prednisone or equivalent) within 1 week prior to Cycle 1 Day 1 (Note: Topical, inhaled, nasal, and ophthalmic steroids are not prohibited)
  • Known allergic reactions or sensitivity to nuvisertib, or similar compound.
  • Splenic irradiation within 6 months prior to Screening or prior splenectomy
  • Prior allogeneic stem cell transplant within the last 6 months (Note: Patients who have relapsed after 6 months post-transplant and do not have active GVHD are eligible).
  • Eligible for allogeneic bone marrow or stem cell transplantation (Note: Patients who are not willing to undergo transplantation or for whom a suitable donor is not available are considered as transplant ineligible.)
  • Major surgery within 4 weeks prior to Cycle 1 Day 1 and/or have not recovered adequately prior to first dose.
  • Active, uncontrolled bacterial, viral, or fungal infections, requiring parenteral antimicrobial within 1 week prior to Cycle 1 Day 1
  • Chronic active or acute viral hepatitis A, B, or C infection (testing for hepatitis B and C are required)
  • Known history of chronic liver disease (eg, portal hypertension or any of its complications, cirrhosis, Child-Pugh C, auto-immune hepatitis, alpha-1 anti-trypsin deficiency, Wilson's disease, etc) (Note: Abnormal liver morphology at baseline imaging may require additional testing, as needed).
  • Unresolved Grade ≥ 2 non-hematological adverse events related to prior treatment (stable Grade 2 conditions may be permitted in consultation with the Sponsor)
  • History of myocardial infarction or symptomatic congestive heart failure or uncontrolled arrhythmia within 6 months prior to Cycle 1 Day 1; LVEF <45% by echocardiogram within 4 weeks prior to Cycle 1 Day 1
  • Corrected QTcF of > 480 msec
  • Prior or concurrent malignancy that could interfere with the safety or efficacy assessment of the study intervention
  • History of a medical condition or GI tract surgery that could impair absorption or could result in short bowel syndrome with diarrhea
  • Known clinically significant anemia due to iron, vitamin B12, or folate deficiencies, or autoimmune or hereditary hemolytic anemia, or thalassemia, or severe GI bleeding
  • Pregnant or breastfeeding

Nuvisertib (TP-3654) + Momelotinib Arm:

  • Received previous systemic antineoplastic therapy or any experimental therapy within 2 weeks or 5 half-lives, whichever is longer, prior to Cycle 1 Day 1 (Notes: Prior treatment with momelotinib or nuvisertib is not allowed; in patients with ongoing JAK inhibitor therapy, ie, ruxolitinib, at screening, JAK inhibitor therapy must be tapered over a period of at least 1 week. Patients on a low dose of ruxolitinib (eg, 5 mg QD) may have a reduced taper period or no taper; hydroxyurea or anagrelide are allowed up to 24 hours prior to Cycle 1 Day 1).
  • Received systemic steroid therapy (>10 mg daily prednisone or equivalent) within 1 week prior to Cycle 1 Day 1 (Note: Topical, inhaled, nasal, and ophthalmic steroids are not prohibited).
  • Known allergic reactions or sensitivity to nuvisertib, momelotinib, or any structurally similar drug, or to any component of the formulations of either study intervention
  • Splenic irradiation within 6 months prior to screening or prior splenectomy
  • Prior allogenic stem cell transplant within the last 6 months (Note: Patients who have relapsed after 6 months post-transplant and do not have active GVHD are eligible).
  • Eligible for allogeneic bone marrow or stem cell transplantation (Note: Patients who are not willing to undergo transplantation or for whom a suitable donor is not available are considered as transplant ineligible).
  • Major surgery within 4 weeks prior to Cycle 1 Day 1 and/or have not recovered adequately from surgery prior to first dose.
  • Active, uncontrolled bacterial, viral, or fungal infections, requiring parenteral antimicrobial within 1 week prior to Cycle 1 Day 1
  • Chronic active or acute viral hepatitis A, B, or C infection (testing for hepatitis B and C are required)
  • Known history of chronic liver disease (eg, portal hypertension or any of its complications, cirrhosis, Child-Pugh C, auto-immune hepatitis, alpha-1 anti-trypsin deficiency, Wilson's disease, etc) (Note: Abnormal liver morphology at baseline imaging may require additional testing, as needed)
  • Unresolved Grade ≥ 2 non-hematological adverse events related to prior treatment (stable Grade 2 conditions may be permitted in consultation with the Sponsor)
  • Presence of Grade ≥ 2 peripheral neuropathy
  • History of myocardial infarction or symptomatic congestive heart failure or uncontrolled arrhythmia within 6 months prior to Cycle 1 Day 1; LVEF < 45% by echocardiogram within 4 weeks prior to Cycle 1 Day 1
  • Corrected QTcF of > 480 msec
  • Prior or concurrent malignancy that could interfere with the safety or efficacy assessment of the study intervention
  • History of a medical condition or GI tract surgery that could impair absorption or could result in short bowel syndrome with diarrhea
  • Known clinically significant anemia due to iron, vitamin B12, or folate deficiencies, or autoimmune or hereditary hemolytic anemia, or thalassemia, or severe GI bleeding
  • Pregnant or breastfeeding

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Non randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Braccio 1: nuvisertib (TP-3654)

Oral PIM Inhibitor

Altri nomi:
  • TP-3654
Sperimentale: Braccio 2: nuvisertib (TP-3654) aggiunto a ruxolitinib

Oral PIM Inhibitor

Altri nomi:
  • TP-3654

Oral JAK inhibitor

Altri nomi:
  • Jakafi
Sperimentale: Braccio 3: nuvisertib (TP-3654) in combinazione con momelotinib

Oral PIM Inhibitor

Altri nomi:
  • TP-3654

Oral JAK inhibitor

Altri nomi:
  • Ojjaara

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Determine the incidence of dose-limiting toxicities (DLTs)
Lasso di tempo: 28 days

Number of participants with DLTs

28 days
Determine the incidence of treatment emergent adverse events
Lasso di tempo: From start of treatment to end of study

Number of participants with Treatment Emergent Adverse Events and Serious Adverse Events

From start of treatment to end of study
Assess patients for any evidence of preliminary activity by determining the number of patients with ≥ 35% spleen volume reduction (SVR35)
Lasso di tempo: From start of treatment to end of study

Number of participants with ≥ 35% spleen volume reduction (SVR35)

From start of treatment to end of study

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Number of participants achieving objective response by IWG-MRT response criteria
Lasso di tempo: From start of treatment to end of study

Number of participants achieving complete remission, partial remission, clinical improvement, progressive disease and stable disease.

From start of treatment to end of study
Number of participants who have ≥ 25% spleen volume reduction
Lasso di tempo: Every 12 weeks from cycle 1 day 1 through cycle 19 day 1, and then every 24 weeks therafter during treatment.

Number of participants who have ≥ 25% spleen volume reduction compared to baseline

Every 12 weeks from cycle 1 day 1 through cycle 19 day 1, and then every 24 weeks therafter during treatment.
Number of participants with ≥ 50% improvement in total symptom score (TSS50) at week 24
Lasso di tempo: 24 weeks

Number of participants who have ≥ 50% total symptom score reduction by MFSAF compared to baseline after 24 weeks of treatment.

24 weeks
Determine the change in Patient Global Impression of Change (PGIC) at week 24 through end of study.
Lasso di tempo: After 24 weeks of treatment to end of study

Change in PGIC score

After 24 weeks of treatment to end of study
Determine the incidence of QT interval changes
Lasso di tempo: 25 hours

Changes in QT interval and heart rhythm

25 hours
Establish the half-life (t½) of nuvisertib monotherapy, in combination with ruxolitinib, and in combination with momelotinib
Lasso di tempo: 24 hours

The estimate of time for the nuvisertib concentration or amount to be reduced by half

24 hours
Establish the Area under the plasma concentration versus time curve (AUC) of nuvisertib monotherapy, in combination with ruxolitinib, and in combination with momelotinib
Lasso di tempo: 24 hours

The amount of drug exposure over 24 hours period after administration

24 hours
Establish the Peak Plasma Concentration (Cmax) of nuvisertib monotherapy, in combination with ruxolitinib, and in combination with momelotinib
Lasso di tempo: 24 hours

The maximum nuvisertib concentration after administration

24 hours
Establish the Time of Maximum concentration observed (tmax) of nuvisertib monotherapy, in combination with ruxolitinib, and in combination with momelotinib
Lasso di tempo: 24 hours

The time to reach maximum nuvisertib concentration

24 hours

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Numero di pazienti con riduzione della fibrosi del midollo osseo
Lasso di tempo: Ogni 24 settimane fino alla fine dello studio
Ogni 24 settimane fino alla fine dello studio
Bracci di associazione con nuvisertib: valutare l’aumento dell’emoglobina ≥ 1,5 o ≥ 2 g/dl rispetto al basale
Lasso di tempo: Dall'inizio del trattamento alla fine dello studio
Dall'inizio del trattamento alla fine dello studio
Bracci di combinazione con Nuvisertib: valutare lo stato di indipendenza dalle trasfusioni di globuli rossi o qualsiasi modifica dei requisiti
Lasso di tempo: Dall'inizio del trattamento alla fine dello studio
Dall'inizio del trattamento alla fine dello studio
Nuvisertib Monoterapia: cambiamenti nella conta piastrinica nel tempo nei pazienti con conta piastrinica basale <100 x 10^9/L
Lasso di tempo: Dall'inizio del trattamento alla fine dello studio
Dall'inizio del trattamento alla fine dello studio
Study potential pharmacodynamic (PD) markers of nuvisertib
Lasso di tempo: 12 months

Evaluate exploratory biomarkers, including change in protein phosphorylation and inflammatory cytokines, in peripheral blood samples and bone marrow biopsy samples.

12 months
Establish overall survival
Lasso di tempo: From start of treatment to end of study

The time interval from treatment start date to date of death from any cause

From start of treatment to end of study

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

16 dicembre 2019

Completamento primario (Stimato)

30 aprile 2027

Completamento dello studio (Stimato)

30 aprile 2030

Date di iscrizione allo studio

Primo inviato

8 novembre 2019

Primo inviato che soddisfa i criteri di controllo qualità

22 novembre 2019

Primo Inserito (Effettivo)

25 novembre 2019

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

2 ottobre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

30 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi